development of osteonecrosis of the jaw in multiple myeloma patients treated with bisphosphonates. The aim of this study was to validate the frequency of SNP rs193451 in 79 patients with multiple myeloma. In 9 (22%) patients developing osteonecrosis of the jaw an heterozygous genotype was found, in contrast with those who did not (n=4, 11%) or healthy individuals (n=6, 13%). We found no differences in the cumulative risk of developing osteonecrosis of the jaw between patients homozygous and heterozygous for major allele. We were unable to confirm a significant association between this polymorphism and the risk of developing osteonecrosis of the jaw.
INTRODUCTION
Multiple myeloma (MM) is characterized by anemia, increased susceptibility to infections and severe pain as a result of osteolytic lesions. The destruction of bone is the result of multiple factors and causes several skeletal complications such as bone pain, pathological fractures, spinal cord compression, and hypercalcemia 1, 2 . Many of these complications are associated with significant morbidity and can negatively impact survival 2 . To reduce and delay the skeletal morbidity caused by MM, treatment with bisphosphonates (BP) has become the standard of care for patients with MM and bone disease 3 .
Osteonecrosis of the jaw (ONJ) is an uncommon but potentially serious complication of intravenous BPs, which is characterized by the presence of exposed bone in the mouth 4, 5 .
Currently, the cause of ONJ is uncertain and likely multifactorial. The risk for ONJ increases with BP treatment duration and has been shown to be 5% -15% at 4 years 2 . Although ONJ has been described during the therapy with any BP, the possibility of developing ONJ may increase with the use of the more potent BPs, with a higher incidence for zoledronic acid (ZOL) 6, 7, 8 . The aim of this study was to validate the incidence of SNP rs1934951 polymorphism in an independent series of patients with MM treated with BPs therapy.
DESIGN AND METHODS
Two series of patients from the University Hospital La Fe (Valencia, Spain, 59 patients) and the Alexandra General Hospital (Athens, Greece, 20 patients) diagnosed with MM with and without ONJ were pooled and studied for the incidence of the rs1934951 polymorphism.
Clinical and biologic characteristics of the patients at diagnosis and their response to therapy were homogeneous between both series (Table 1) . Taking all together, a total of 79 patients Fisher's exact test was used to test for the allelic association between SNP rs1934951 and ONJ. Unadjusted time-to-event analyses were performed using the Kaplan-Meier 14 estimate
and, for comparisons, log-rank tests 15 . The probability of ONJ was also estimated by the cumulative incidence method, and univariate comparison between the curves was performed using the Gray test 16 . All descriptive statistics and tests were performed using the statistical package SPSS, version 17.0 (SPSS Inc., Chicago, IL, USA) and R 2.7.2 software package.
P<0.05 was considered significant.
RESULTS AND DISCUSSION
The series included 45 (54%) males and 38 (46%) females with a median age of 62 years (range, 26 to 87). The median follow-up was 84 months (range, 10 to 256). Homozygous genotype for the major allele (CYP2C8 CC ) was the most frequent genotype in the three populations studied and was observed in 32 (76%) patients with ONJ, in 33 (89%) patients without ONJ, and in 39 (86%) healthy volunteers. These proportions were somewhat higher than the previously reported in SNP databases (Table 1) . Conversely, heterozygous genotype (CYP2C8 CT ) was present in 9 patients with ONJ (22%), in 4 patients without ONJ (11%), and in 6 healthy volunteers (13%). Finally, only one of the individuals analyzed was found to be homozygous for the T allele (Table 1) . Thus, although roughly double of the MM patients developing ONJ showed heterozygous genotype CYP2C8 CT as compared with MM patients who did not develop ONJ or healthy individuals, these differences did not reach statistical significance (P = 0.13). These results contrast with those reported by Sarasquete et al who found a 66% of heterozygous genotype CYP2C8 CT in MM cases with ONJ versus 25% of controls 9 . Additionally, they also found a 14% homozygous for the CYP2C8 TT allele within the ONJ group versus 0% within the controls. 9 It could be also stated that the limited number of cases in both groups could influence the results, however, our P values are far away from the previously published differences by Sarasquete et al. 9 As these borderline results precluded us to extract solid conclusions, we estimated the cumulative incidence of developing ONJ in patients with CYP2C8 CT genotype and in patients with CYP2C8 CC genotype. At 3 years, actuarial risk for patients with CYP2C8 CT genotype was 35% and for those with CYP2C8 CC was 53%, showing no statistically significant differences.
Besides minor differences in the methodologies employed in both studies, several factors could explain, at least in part, the differences observed in the CYP2C8 allele proportion between our series and in the previously reported by Sarasquete et al. 9 First, due to small numbers, it could not be discarded a bias in patient selection between both series. Second, patients in the previous series were uniformly treated with polychemotherapy followed by autologous transplant whereas in our series patients received different induction regimens including new drugs (thalidomide). Additionally, all patients in our study received ZOL as BP therapy whereas in the series by Sarasquete et al. pamidronate was the main BP administered. 9 Finally, in our series we could not evaluate the potential role of oral risk factors (oral surgery, previous dental assessment, control of pre-existing implants and prosthesis...) as well as the use of prevention-based strategies in the development of ONJ in this group of patients 18 , a fact that could help to explain the different results observed in both studies.
Overall, although our results showed a trend towards a higher proportion of the SNP rs1934951 polymorphism on CYP2C8 gene in those patients developing ONJ, the cumulative Table 2 . (http://www.ncbi.nlm.nih.gov/projects/SNP)
